



Claims

- 1) A method for the treatment of co-morbid conditions associated with obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of formula I



including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl, and a therapeutically effective amount of a compound of formula II



wherein the compound of formula I and the compound of formula II are administered simultaneously, separately or sequentially.

- 2) A method according to claim 1 in which the compound of formula I is N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine or a salt thereof.

3) A method according to claim 2 wherein the compound of formula I is administered 30 minutes to 3 hours prior to the administration of the compound of formula II.

4) A compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.


SUB
AI

5) A compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.


6) A product containing a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.

7) The use of a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl in the manufacture of a medicament for the treatment of co-morbid conditions associated with obesity in a patient who is also receiving treatment with orlistat.

8) A pharmaceutical composition comprising a compound of formula I




including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl, and the compound of formula II




in conjunction with a pharmaceutically acceptable diluent or carrier.

Abstract

A method for the treatment of co-morbid conditions associated with obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of formula I



including enantiomers and pharmaceutically acceptable salts thereof, in which R₁ and R₂ are independently H or methyl, and a therapeutically effective amount of a compound of formula II



wherein the compound of formula I and the compound of formula II are administered simultaneously, separately or sequentially.

00009833 121701
T0722T E286000